Oncimmune announce IPO on AIM

Balderton

Oncimmune announce IPO on AIM

MAY 18, 2016

Geoffrey Hamilton-Fairley, CEO of Oncimmune

We are delighted that Oncimmune have today announced their IPO. The company have developed and patented a technology that detects cancer in its early stages, when the possibility of a cure is highest.

Balderton led a £5.25m round into Oncimmune in 2007, with Tim Bunting joining the board.

Congratulations to Geoffrey Hamilton-Fairley and the Oncimmune team, we look forward to their journey as a public company.

You can watch Geoffrey’s interview with CNBC here

Take me back

Oncimmune announce IPO on AIM

Balderton

Oncimmune announce IPO on AIM

MAY 18, 2016

Share

Related content

Agave Games secures $18 Million Series A to expand hit game ‘Find the Cat’ and develop new titles

Lawhive raises $40M to expand its legal AI platform in the US

Congratulating Dream Games on the launch of their second game, Royal Kingdom

Kong secures $175M new financing at $2bn valuation to power the API world

The Exploration Company raises $160 million to build the first European space capsule

Writer raises $200M to fuel leadership in enterprise AI

AI’s transformational power: Insights from Balderton’s autumn event series

Unlocking founder potential: A new leadership development program for growth-stage CEOs

The business case for founder wellbeing – reflections on our second annual survey

Thor Mitchell joins Balderton as Executive In Residence

Convergence raises $12M to build personal AI agents with long-term memory

DELLI raises $6M to accelerate its independent food and drink platform

Reflecting on Balderton’s first team Impact Day

Wayve and Uber partner to accelerate the future of automated driving

Attio raises $33 million in funding